Results 91 to 100 of about 791,647 (284)

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Clinical Pharmacology &Therapeutics, EarlyView.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Pulmonary T-cell lymphoma masquerading as eosinophilic pneumonitis

Lung India, 2019
Primary pulmonary T-cell lymphoma is an unusual subtype of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). This is a general term used to describe a diverse group of T-cell-type lymphomas that would otherwise not be classified as a PTCL ...
Najam Siddiqui, Kevin Charles, Ashley E Ferraro, Robert C Holladay, Jeremy C Johnson, Satish Kalanjeri   +5 more
doaj   +1 more source

Primary pulmonary MALT lymphoma presenting as non-resolving pneumonia [PDF]

, 2017
  Primary lung lymphoma (PLL) is a rare unilateral or bilateral lung disorder that is challenging to diagnose solely based on clinical and radiological presentation. PLL may be misdiagnosed as pneumonia or a lung tumor due to non-specific findings.
Iftikhar, Asma; New York Presbyterian Hospital Queens Department of Pulmonary, Critical Care and Sleep Medicine 56-45 Main Street. Flushing, NY 11355, Magh, Albert; New York Presbyterian Hospital Queens Department of Pulmonary, Critical Care and Sleep Medicine 56-45 Main Street. Flushing, NY 11355, Sahni, Sonu; Northwell Health System New Hyde Park, NY 11040 Touro College of Osteopathic Medicine Department of Primary Care 230 W. 125th Street. New York, NY 11027, Cheema, Muhammed Azaz; Northwell Health System New Hyde Park, NY 11040, Karbowitz, Stephen; New York Presbyterian Hospital Queens Department of Pulmonary, Critical Care and Sleep Medicine 56-45 Main Street. Flushing, NY 11355, Thappa, Sarah; Touro College of Osteopathic Medicine Department of Primary Care 230 W. 125th Street. New York, NY 11027   +5 more
core   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma [PDF]

, 2004
Historically localised aggressive non-Hodgkin's lymphoma (NHL) has been treated with involved field radiotherapy (RT), chemotherapy, or a combination of both modalities. The current weight of evidence supports a preference for combined modality treatment
P Hoskin, P Smith, Linch, D, J Spicer, B Hancock, Spicer, J, Hoskin, P, R Pettengell, Hancock, B, K Maclennan, Spicer, J; id_orcid, Smith, P, Pettengell, R, D Linch, Maclennan, K   +14 more
core   +1 more source

A case report: Diagnosis and treatment of idiopathic hypertrophic pachymeningitis

Ibrain, Volume 11, Issue 1, Page 112-116, Spring 2025.
We reported a case of idiopathic hypertrophic dura meningitis diagnosed in our hospital. The patient repeatedly suffered from headaches, followed by blurred vision in the right eye. During this period, multiple sclerosis was considered for diagnosis, and it improved after hormone treatment.
Zhong Luo, Piao Cao, Jing‐Qing Xu, Rong Yan, Jian Wang, Tao Liang, Ya Chen, Zu‐Cai Xu   +7 more
wiley   +1 more source

Pulmonary Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma: A Diagnostic Dilemma

Respirology Case Reports
Primary pulmonary lymphoma (PPL) is a rare clonal proliferation of lymphoid tissue confined to the lungs, representing only 0.5%–1% of all lung neoplasms. Pulmonary mucosa‐associated lymphoid tissue (MALT) lymphoma is the most common subtype and is often
Rajan Patel, Diane Stover
doaj   +1 more source

A Rare Case of Primary Pulmonary Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Mucosa-Associated Lymphoid Tissue Lymphoma

Medicina
Primary pulmonary lymphoma is a rare neoplasm characterized by the proliferation of lymphoid tissue affecting the lungs. The most common subtype is marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).
Kajetan Kiełbowski, Dawid Kordykiewicz, Janusz Jesionka, Janusz Wójcik, Konrad Ptaszyński, Konstantinos Kostopanagiotou, Piotr Waloszczyk, Małgorzata Edyta Wojtyś   +7 more
doaj   +1 more source

Pulmonary MALT-lymphoma: case report and literature review

Клиническая онкогематология, 2013
This article presents a rare case of pulmonary MALT-lymphoma and literature review. An elderly patient with pulmonary MALT lymphoma was successfully treated according to R-B (rituximab + bendamustine) chemotherapy program.
A. K. Morozova, N. G. abeeva, E. E. Zvonkov   +2 more
doaj   +1 more source